Abstract Details

Title Modeling Subject-Level Disease Progression for Multiple Sclerosis Clinical Trials with Machine Learning

Topic Multiple Sclerosis

Presentation(s) S54 - Multiple Sclerosis: Disease Progression, Disease-modifying Therapy, and Clinical Considerations (3:42 PM-3:54 PM)

Poster/Presentation
Number 002

Objective To develop a machine-learning model that can accurately predict Multiple Sclerosis (MS) disease progression for individual subjects enrolled in the placebo arm of MS clinical trials.

Background Control arms are a mainstay of clinical trials. Accurately predicting Multiple Sclerosis (MS) disease progression for individual patients in the control arm is valuable for therapeutic development, and can be accomplished with a machine-learning model. The abundance of high-quality subject data, collected repeatedly from control arms in past clinical trials, provides an opportunity to build a model that can predict outcomes for control subjects in future trials.

Design/Methods We used a machine-learning model called the Conditional Restricted Boltzmann Machine (CRBM) that is designed to predict how clinical variables related to MS change over time. To develop this model, we extracted a machine-learning dataset from data provided by the Multiple Sclerosis Outcome Assessments Consortium comprising 2465 placebo arm subjects across 8 MS clinical trials. Our dataset contains 21 variables including demographic information, functional assessments, and disability measurements every 3 months for up to 48 months. We then trained the model and assessed its ability to generate statistically accurate predictions, using a set of test subjects not used during training.

Results Given baseline data for placebo subjects, the CRBM model can generate data for the future clinical state of individual subjects that are statistically indistinguishable from actual subject data along a number of key measures, suggesting the model is capable of generating digital subjects equivalent to actual subjects. Notably, the model accurately captures Expanded Disability Status Scale (EDSS) trajectories and relapse rates across MS subtypes.

Conclusions We have created a subject-level model of MS disease progression that can predict the future state of placebo subjects in clinical trials. Our model has useful applications in clinical trials, including supplementing control arms with digital subjects generated from the model.

Authors/Disclosures
Jonathan Walsh, PhD (Unlearn.AI) PRESENTER	Dr. Walsh has received personal compensation for serving as an employee of Unlearn.AI. Dr. Walsh has received intellectual property interests from a discovery or technology relating to health care.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file

��ɫ��

��ɫ��